These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31970055)

  • 1. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).
    Mark M; Thürlimann B; Ribi K; Schär C; Dietrich D; Cathomas R; Zürrer-Härdi U; von Briel T; Anchisi S; Bohanes P; Blum V; von Burg P; Mannhart M; Caspar CB; von Moos R
    J Bone Oncol; 2020 Apr; 21():100273. PubMed ID: 31970055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).
    Ribi K; Thürlimann B; Schär C; Dietrich D; Cathomas R; Zürrer-Härdi U; von Briel T; Anchisi S; Bohanes P; Blum V; von Burg P; Mannhart M; Caspar CB; von Moos R; Mark M
    BMC Cancer; 2021 Feb; 21(1):182. PubMed ID: 33607966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
    Stoffel ST; von Moos R; Thürlimann B; Cathomas R; Gillessen S; Zürrer-Härdi U; von Briel T; Anchisi S; Feller A; Schär C; Dietrich D; Schwenkglenks M; Lupatsch JE; Mark MT
    Swiss Med Wkly; 2021 Mar; 151():w20464. PubMed ID: 33705559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.
    Body JJ; von Moos R; Rider A; Hallworth P; Bhowmik D; Gatta F; Hechmati G; Qian Y
    J Bone Oncol; 2019 Feb; 14():100212. PubMed ID: 30627511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.
    von Moos R; Body JJ; Rider A; de Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
    J Bone Oncol; 2018 Jun; 11():1-9. PubMed ID: 29892519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.
    Jakob A; Zahn MO; Nusch A; Werner T; Schnell R; Frank M; Hamm N; Däßler KU; Losem C; Welslau M; Hoevel P; Potthoff K
    J Bone Oncol; 2022 Apr; 33():100420. PubMed ID: 35340302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
    Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
    J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
    Cadieux B; Coleman R; Jafarinasabian P; Lipton A; Orlowski RZ; Saad F; Scagliotti GV; Shimizu K; Stopeck A
    J Bone Oncol; 2022 Apr; 33():100416. PubMed ID: 35242510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
    Clemons M; Ong M; Stober C; Ernst S; Booth C; Canil C; Mates M; Robinson A; Blanchette P; Joy AA; Hilton J; Aseyev O; Pond G; Jeong A; Hutton B; Mazzarello S; Vandermeer L; Kushnir I; Fergusson D;
    Eur J Cancer; 2021 Jan; 142():132-140. PubMed ID: 33023785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study.
    Mark M; Mora AR; Winder T; Stathis A; Jakob A; Müller G; Hayoz S; Reimann P; Petrausch U; von Moos R;
    Bone Rep; 2024 Sep; 22():101794. PubMed ID: 39139592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
    Phillips WJ; Saad F; Leigh J; Jooya A; Webber C; Morgan S; MacRae R; Bourque JM; Tanuseputro P; Ong M
    Oncologist; 2024 Mar; ():. PubMed ID: 38527096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases.
    Lobo-Martins S; Ferreira AR; Mansinho A; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.
    Clemons M; Liu M; Stober C; Pond G; Jemaan Alzahrani M; Ong M; Ernst S; Booth C; Mates M; Abraham Joy A; Aseyev O; Blanchette P; Vandermeer L; Tu M; Thavorn K; Fergusson D;
    J Bone Oncol; 2021 Oct; 30():100388. PubMed ID: 34567960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
    Henry D; von Moos R; Body JJ; Rider A; De Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
    Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
    Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
    Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe.
    von Moos R; Lewis K; Massey L; Marongiu A; Rider A; Seesaghur A
    Bone; 2022 Jan; 154():116243. PubMed ID: 34757213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer.
    Tu MM; Clemons M; Stober C; Jeong A; Vandermeer L; Mates M; Blanchette P; Joy AA; Aseyev O; Pond G; Fergusson D; Ng TL; Thavorn K
    Curr Oncol; 2021 May; 28(3):1847-1856. PubMed ID: 34068083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
    D'Oronzo S; Coleman R; Brown J; Silvestris F
    J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
    Gómez Rivas J; Carrion DM; Alvarez-Maestro M; Cathelineau X; Sanchez-Salas R; Di Lorenzo G; Di Maio M; Paul A; Martinez-Piñeiro L; Sartor O; Saad F; Debruyne F
    Minerva Urol Nefrol; 2019 Oct; 71(5):445-456. PubMed ID: 31353876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.